Weighing the Trade-offs of a Direct Presence in Japan’s Rare and Orphan Drug Market

In recent years, there has been a marked uptick in the number of rare and orphan companies establishing local operations in Japan to steward their pipelines through development and to the market. In order to be successful with market entry and maintain a direct presence in Japan, biopharmaceutical companies must develop a thoughtful entry strategy and plan of operation.

Unlocking the Japanese market opportunity will likely require a detailed market assessment, early understanding of the regulatory environment, a key opinion leader engagement plan, and a clinical, market access, pricing and commercialization strategy. This Special Report examines the various workstreams involved in creating a successful Japanese market entry and launch strategy.